Rare diseases
Expansion into new international biotech markets can be challenging. Unfamiliar regulations and licensing, coupled with language and cultural differences, can all be barriers to growth. If you’re considering venturing into Europe and beyond, our easy-to-follow guides, shaped by 30 years of expertise in the rare disease market, will assist you in navigating challenges and gaining a profound understanding of the complexities involved in launching orphan drugs into new markets. To learn more about how Sciensus can facilitate and support your Europan expansion, visit: Rare Diseases and Orphan Drugs
Blogs, Rare diseases
The increasing importance of real-world data for the EMA
Blogs, Rare diseases
Real-world data and shaping the future of healthcare
Blogs, Rare diseases
Six steps for a successful Early Access Program in Europe
Thought Leadership, Rare diseases
Get the free whitepaper: Transitioning from open-label extensions to early access programs
Blogs, Rare diseases
Mitigating risks in early access programmes: A guide for biotech companies
Thought Leadership, Rare diseases
Get the free whitepaper: How early access programs & real-world data help Biotechs succeed
News, Rare diseases
Sciensus partners with Sentynl Therapeutics
News, Rare diseases
Sciensus hosts a webinar with Fierce Biotech
Thought Leadership, Rare diseases
Launching successful patient support programs for rare disease patients across Europe